research Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
Search
for
Sort by
Research
390-420 / 1000+ results
research La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
research A Novel Hope for Alopecia Totalis Patients: Case Report
Tofacitinib may effectively regrow hair in alopecia totalis patients.
research High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata
CD8+ T cells are involved in alopecia areata and may cause disease relapse.
research Treating Alopecia Areata: Current Practices Versus New Directions
New treatments like JAK inhibitors show promise for reversing alopecia areata.
research Excellent response to tofacitinib treatment in a patient with alopecia universalis
A patient with complete hair loss regrew all her hair using tofacitinib.
research A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
research Alopecia areata: medical treatments
Some treatments for autoimmune hair loss work, but JAK inhibitors like tofacitinib are promising for regrowth.
research 008 Stratifying alopecia areata systemic treatments: Tailored approaches to disease severity
Tailored treatments for alopecia areata show promising results, with pulse steroids effective for mild cases and Ritlecitinib, Dupilumab, or methotrexate and prednisone effective for severe cases.
research Alopecia Areata: Current Review
Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.
research Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
research Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
International guidelines for treating alopecia areata vary, focusing on different treatment options and related health issues.
research Alopecia universalis following human papillomavirus vaccine administration: a case report
A woman experienced total hair loss after an HPV vaccine, but treatment helped regrow her hair.
research Interleukin-6 Null Mice Paradoxically Display Increased STAT3 Activity and Wound-Induced Hair Neogenesis
Mice without the IL-6 gene had more hair growth after injury due to higher activity of a related protein, Stat3.
research Impact of Stat3 activation upon skin biology: A dichotomy of its role between homeostasis and diseases
Stat3 helps skin heal but can also cause skin diseases if overactive.
research Abstract 5216: Impact of Stat3 deletion or activation on keratinocyte stem/progenitor cells
Stat3 influences keratinocyte stem cell behavior, affecting differentiation and migration.
research Constitutive Stat3 activation alters behavior of hair follicle stem and progenitor cell populations
Increased Stat3 activity reduces hair follicle stem cells and boosts other stem/progenitor cells.
research ROLE OF STAT3 IN KERATINOCYTE STEM CELLS DURING SKIN TUMORIGENESIS
Stat3 affects skin cancer development by altering keratinocyte stem cell behavior.
research Constitutive activation of S tat3 in mouse epidermis is linked to hair deficiency and cytoskeletal network damage
Overactive Stat3 in mouse skin causes hair loss and cell structure damage.
research Interleukin 6 and STAT3 regulate p63 isoform expression in keratinocytes during regeneration
The conclusion is that the IL-6/STAT3 activation affects p63 expression in healing wounds, which may help in hair follicle regeneration.
research Expression of Signal Transducer and Activator of Transcription-3 in Androgenetic Alopecia: A case control study
Higher STAT3 levels are found in hair loss areas, but not linked to hair loss severity.
research Tissue Regeneration: Hair Follicle as a Model
Stat3 is essential for hair growth and wound healing.
research Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib
This study assessed the immune responses to tetanus and meningococcal vaccines in 17 patients with alopecia areata undergoing ritlecitinib therapy. Results showed that 62.5% of participants had a tetanus booster response, with all achieving protective anti-tetanus antibody levels. For the meningococcal vaccine, 20% and 40% of participants reached specific antibody titers for serogroup C. The vaccines were well tolerated, with no adverse events reported. However, the small sample size limits the conclusions, and further research with larger populations is needed.
research P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research Abstract 4300: Constitutive activation of Stat3 increases hair follicle progenitor population at the expense of bulge region keratinocyte stem cells
Stat3 activation increases hair follicle progenitors but reduces bulge region stem cells.
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
research Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.